- Home
- NEO
NEO
NeoGenomics Inc.
as 07-26-2024 4:00pm EST
NeoGenomics Inc operates a network of cancer-focused genetic testing laboratories in the United States as well as a laboratory in Switzerland. The company operates into two segments namely Clinical Services and Advanced Diagnostics. It offers types of genetic and molecular testing services namely Cytogenetics, Fluorescence In-Situ Hybridization, Flow cytometry, Immunohistochemistry, Molecular testing, Pathology consultation. Advanced Diagnostics segment supports pharmaceutical firms in their drug development programs by supporting various clinical trials and research. For Clinical Services, Its specialized diagnostic services are performed based on an online test order or a written test requisition form. The company generates majority of its revenue from Clinical Services.
Upcoming Earnings Alert:
Get ready for potential market movements as NeoGenomics Inc. NEO prepares to release earnings report on 29 Jul 2024.
| Founded: | 2001 | Country: | United States |
| Employees: | N/A | City: | FORT MYERS |
| Market Cap: | 1.7B | IPO Year: | 1999 |
| Target Price: | $19.78 | AVG Volume (30 days): | 743.4K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.66 | EPS Growth: | N/A |
| 52 Week Low/High: | $11.03 - $21.22 | Next Earning Date: | 07-29-2024 |
| Revenue: | $610,663,000 | Revenue Growth: | 15.27% |
| Revenue Growth (this year): | 11.93% | Revenue Growth (next year): | 9.70% |
Stock Insider Trading Activity of NeoGenomics Inc. (NEO)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Olivo Alicia C | NEO | General Counsel | May 15 '24 | Sell | $15.74 | 1,049 | $16,511.26 | 44,867 | SEC Form 4 |
| TETRAULT LYNN A. | NEO | Director | Mar 4 '24 | Sell | $15.97 | 6,112 | $97,578.69 | 50,062 | SEC Form 4 |
| Olivo Alicia C | NEO | General Counsel | Feb 15 '24 | Sell | $14.96 | 2,587 | $38,712.90 | 34,866 | SEC Form 4 |
| Olivo Alicia C | NEO | General Counsel | Nov 17 '23 | Sell | $18.39 | 2,669 | $49,082.91 | 37,140 | SEC Form 4 |
Latest NeoGenomics Inc. News
NEO Breaking Stock News: Dive into NEO Ticker-Specific Updates for Smart Investing
Argus Research
3 days ago
NEO: Lowering target price to $12.00
Simply Wall St.
4 days ago
NeoGenomics (NASDAQ:NEO) shareholders have endured a 68% loss from investing in the stock three years ago
Insider Monkey
7 days ago
Is NeoGenomics, Inc. (NEO) the Most Profitable Stock of the Last 20 Years?
Argus Research
10 days ago
NEO: Raising target price to $13.00
Argus Research
17 days ago
NEO: What does Argus have to say about NEO?
Business Wire
18 days ago
NeoGenomics to Report Second Quarter 2024 Financial Results on July 29, 2024
Argus Research
24 days ago
NEO: Raising target price to $11.00
Business Wire
a month ago
Fort Myers’ Mayor to Proclaim June as NeoGenomics’ Commitment to Cancer Month
Compare NEO vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "NEO NeoGenomics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.